Last reviewed · How we verify
NCT06843265: JADAValle
Outcomes and Perceptions of the Implementation of the JADA Device in a Stage II Postpartum Hemorrhage Management Protocol in Referral Hospitals of the Colombian Pacific Region
NA trial testing Vacuum- Induce Hemorrhage Control in Post Partum Haemorrhage in 24 participants. Not yet recruiting.
31 December 2025
Quick facts
| Lead sponsor | Fundacion Clinica Valle del Lili |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 1 June 2025 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
Drugs / interventions tested
- Vacuum- Induce Hemorrhage Control
Conditions studied
- Post Partum Haemorrhage — all drugs for Post Partum Haemorrhage →
Sponsor
Fundacion Clinica Valle del Lili
Who can join
18 and older, female only, with Post Partum Haemorrhage. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study focuses on postpartum hemorrhage (PPH), a condition that stands out as the leading cause of global maternal mortality. Annually, about 14 million women experience PPH, resulting in approximately 70,000 deaths. This condition presents a higher risk in low- and middle-income countries (LMICs), particularly where access to quality care is limited. Recognizing the urgency of addressing this public health problem, the Colombian Ministry of Health and Social Protection has implemented the Maternal Mortality Reduction Acceleration Plan (PARE) to improve maternal mortality indicators and meet the Sustainable Development Goals (SDGs). The project will evaluate the results and perception of a new device in the management of stage II PPH in referral hospitals in the department of Valle del Cauca, integrated in the Hospital Padrino strategy. This initiative seeks not only to improve the understanding and treatment of PPH, but also to strengthen institutional capacities through education, creation of telecare networks and care services adapted to local needs.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06843265
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Post Partum Haemorrhage
Currently open trials in the same condition.
- NCT06655207 — Pivotal, Prospective, Multi-centre, Single-arm Study to Evaluate the Safety and Effectiveness of Oli for Identification · NA · recruiting
Other Fundacion Clinica Valle del Lili trials
Trials by the same sponsor.
- NCT06875791 — Safety and Efficacy Trial of TV5M01 for Radiation-Induced Mucositis in Head and Neck Cancer Patients. · Phase 1, PHASE2 · not yet recruiting
- NCT06620432 — High Vs. Low Segmental Hysterotomy: Impact on Uterine Wall Defects Post-Cesarean · NA · not yet recruiting
- NCT06086080 — Non-operative Treatment in First-time Patellar Dislocation · NA · recruiting
- NCT05922397 — Placenta Accreta Spectrum Topographic Classification · recruiting
- NCT05295641 — American Registry of Ambulatory or Acutely Decompensated Heart Failure · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06843265 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fundacion Clinica Valle del Lili
- Last refreshed: 24 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06843265.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing